Gossamer Bio, Inc. (GOSS): Operating Income
-$170.73M
Year ended 2025-12-31
-$166.09M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$170.73M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$59.92M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$183.76M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$218.59M | n/m | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | -$216.12M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | -$233.96M | n/m | 2023-03-17, From 2020-01-01 |
| 2019-12-31 | -$186.14M | n/m | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | -$148.99M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$6.65M | n/a | 2020-03-24, From 2017-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.73M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$48.91M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | -$158.13M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | -$68.30M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$270.02M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$71.05M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | -$2.79M | n/m |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | -$2.71M | n/m |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$41.98M | n/m |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗